Understanding the Science of Yeast Infections

At a Glance

Vulvovaginal candidiasis occurs when Candida overgrows or changes form in the vagina, triggering inflammation that causes itching, burning, redness, and swelling. Identifying the Candida species and using microscopy or culture can guide effective treatment.

If you are dealing with the itching, burning, and discomfort of a yeast infection, you are far from alone. Vulvovaginal Candidiasis (VVC)—the medical term for a vaginal yeast infection—is one of the most common reasons women seek medical care. Approximately 75% of women will experience at least one episode in their lifetime ^[1]^[2]. For some, it becomes a recurring challenge, with about 4% of women globally experiencing four or more infections in a single year ^[3].

While VVC can be intensely frustrating and uncomfortable, understanding the biology of how it happens can help you and your doctor find the most effective path to relief.

The Resident Yeast: From Harmless to Pathogenic

In many cases, the fungus that causes these infections, Candida, lives harmlessly in the vagina without causing any symptoms. When it lives there peacefully, it is called a commensal (a resident that doesn’t cause harm) ^[4]. In fact, at least 20% of women carry Candida as part of their normal vaginal environment ^[2].

A yeast infection occurs not just because the yeast is present, but because the balance of the vaginal environment shifts. When conditions change—due to factors like hormone shifts, antibiotic use, or changes in the immune system—the yeast can overgrow and change its physical form. In the case of Candida albicans, it transforms from a round, yeast-like cell into long, branch-like structures called hyphae ^[4]^[5]. These hyphae are associated with causing symptoms and can begin to interact with the surface of the vaginal tissue.

Why It Hurts: The Role of Candidalysin

It is a common misconception that the yeast itself is what causes all the pain. In reality, much of the intense burning and swelling is caused by your own immune system responding to factors like candidalysin, a peptide secreted by the hyphae of C. albicans ^[6].

As the yeast grows into its hyphal form, it secretes candidalysin, which damages the surface cells of the vagina ^[7]. Your body senses this damage and sounds the alarm, triggering a powerful inflammatory response. This brings in neutrophils—the body’s “first responder” white blood cells ^[8]. While these cells are trying to help, their arrival in large numbers contributes to the swelling, redness, and irritation you feel ^[7]. Essentially, your symptoms are in part the result of an inflammatory response happening in the vaginal tissue ^[9].

Why the Species of Yeast Matters

Not all yeast infections are caused by the same organism. Identifying which species is present is critical, especially if your infection keeps coming back or doesn’t respond to standard over-the-counter treatments.

Candida albicans: This is the most common species, responsible for about 70% to 80% of infections ^[10]^[11]. It usually responds well to standard antifungal medications (azoles) like fluconazole or miconazole.
Non-albicans species: This group includes species like Candida glabrata, which typically does not form hyphae but is still a significant cause of VVC. These are less common but are often found in infections that are difficult to treat or that recur frequently ^[12]. These species can be naturally less susceptible to standard antifungal treatments ^[13]^[14].

If you have what doctors call complicated VVC—which includes infections that are severe, recurrent, or caused by non-albicans species—a simple one-day treatment may not be enough ^[15].

Navigating the Diagnosis

Because many different conditions (like bacterial vaginosis or skin irritation) can mimic the symptoms of a yeast infection, a precise diagnosis is essential.

Microscopy: Your doctor may look at a sample of vaginal fluid under a microscope to check for the presence of yeast and hyphae ^[16].
Culture: If treatments aren’t working, your doctor may perform a fungal culture. This involves growing the yeast in a lab to identify exactly which species is present ^[17].
Susceptibility Testing: In persistent cases, the lab can test the yeast to see which specific medications are most effective at killing it ^[18].

Understanding that VVC is a complex interaction between the yeast and your immune system can help you move away from frustration and toward a management plan that addresses the root cause of your symptoms.

Common questions in this guide

Why can Candida cause symptoms if it normally lives in the vagina?

Candida can normally live in the vagina without causing symptoms. Antibiotics, hormone shifts, or changes in the immune system can upset the local balance, allowing it to overgrow and change into forms that irritate tissue.

What causes the burning and swelling of a vaginal yeast infection?

Burning and swelling are partly caused by the body’s immune response, not only by the yeast itself. A substance called candidalysin can damage surface cells, prompting white blood cells to create inflammation.

Why does the Candida species matter when choosing treatment?

Candida albicans causes most vulvovaginal yeast infections and often responds to azole medicines such as fluconazole or miconazole. Non-albicans species, including Candida glabrata, may be less sensitive to standard treatment, so identifying the species can help guide medication.

How is vulvovaginal candidiasis diagnosed?

A clinician may evaluate your symptoms and examine a vaginal-fluid sample under a microscope for yeast or thread-like forms. If the diagnosis is uncertain or treatment is not working, a fungal culture can identify the species, and susceptibility testing can help show which medicines are likely to work.

When might I need a fungal culture for a yeast infection?

A culture is especially useful when symptoms recur, the infection is severe, or standard treatment has not worked. It can identify non-albicans Candida, and susceptibility testing may help when the organism is less responsive to usual antifungal medicines.

What makes vulvovaginal candidiasis complicated?

Complicated vulvovaginal candidiasis includes severe infections, recurrent infections, and infections caused by non-albicans species. These cases may need more testing or a treatment plan that differs from a simple one-day course.

Get notified when new evidence is published on vulvovaginal candidiasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
Sherry L, Kean R, McKloud E, et al.
Antimicrobial agents and chemotherapy 2017; (61(9)) doi:10.1128/AAC.01065-17.
PMID: 28696240
2
Recurrent vulvovaginal candidiasis.
Blostein F, Levin-Sparenberg E, Wagner J, Foxman B
Annals of epidemiology 2017; (27(9)):575-582.e3 doi:10.1016/j.annepidem.2017.08.010.
PMID: 28927765
3
Global burden of recurrent vulvovaginal candidiasis: a systematic review.
Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R
The Lancet. Infectious diseases 2018; (18(11)):e339-e347 doi:10.1016/S1473-3099(18)30103-8.
PMID: 30078662
4
It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With Candida Virulence, Triggers VVC Onset.
Ardizzoni A, Wheeler RT, Pericolini E
Frontiers in microbiology 2021; (12()):692491 doi:10.3389/fmicb.2021.692491.
PMID: 34163460
5
A Role for Yeast/Pseudohyphal Cells of Candida albicans in the Correlated Expression of NLRP3 Inflammasome Inducers in Women With Acute Vulvovaginal Candidiasis.
Roselletti E, Monari C, Sabbatini S, et al.
Frontiers in microbiology 2019; (10()):2669 doi:10.3389/fmicb.2019.02669.
PMID: 31803172
6
Processing of Candida albicans Ece1p Is Critical for Candidalysin Maturation and Fungal Virulence.
Richardson JP, Mogavero S, Moyes DL, et al.
mBio 2018; (9(1)) doi:10.1128/mBio.02178-17.
PMID: 29362237
7
Candidalysin Drives Epithelial Signaling, Neutrophil Recruitment, and Immunopathology at the Vaginal Mucosa.
Richardson JP, Willems HME, Moyes DL, et al.
Infection and immunity 2018; (86(2)) doi:10.1128/IAI.00645-17.
PMID: 29109176
8
NLRP3 inflammasome is a key player in human vulvovaginal disease caused by Candida albicans.
Roselletti E, Perito S, Gabrielli E, et al.
Scientific reports 2017; (7(1)):17877 doi:10.1038/s41598-017-17649-8.
PMID: 29259175
9
Vaginal Heparan Sulfate Linked to Neutrophil Dysfunction in the Acute Inflammatory Response Associated with Experimental Vulvovaginal Candidiasis.
Yano J, Noverr MC, Fidel PL
mBio 2017; (8(2)) doi:10.1128/mBio.00211-17.
PMID: 28292981
10
Prevalence, antifungal susceptibility and etiology of vulvovaginal candidiasis in sub-Saharan Africa: a systematic review with meta-analysis and meta-regression.
Mushi MF, Olum R, Bongomin F
Medical mycology 2022; (60(7)) doi:10.1093/mmy/myac037.
PMID: 35781514
11
Epidemiology of vulvovaginal candidiasis in China: a six-year retrospective single-center study from a tertiary obstetrics and gynecology hospital in Shanghai.
Chen Y, Lu L, Wang Q, et al.
Microbiology spectrum 2026; e0325125 doi:10.1128/spectrum.03251-25.
PMID: 41944636
12
Species Distribution and Antifungal Susceptibility Profiles of Isolates from Women with Nonrecurrent and Recurrent Vulvovaginal Candidiasis.
Rolo J, Faria-Gonçalves P, Barata T, et al.
Microbial drug resistance (Larchmont, N.Y.) 2021; (27(8)):1087-1095 doi:10.1089/mdr.2020.0139.
PMID: 33646045
13
Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis.
Shi Y, Zhu Y, Fan S, et al.
BMC infectious diseases 2020; (20(1)):287 doi:10.1186/s12879-020-04985-w.
PMID: 32393342
14
Molecular epidemiology and antimicrobial resistance of vaginal Candida glabrata isolates in Namibia.
Dunaiski CM, Kock MM, Chan WY, et al.
Medical mycology 2024; (62(2)) doi:10.1093/mmy/myae009.
PMID: 38308518
15
Genital cutaneous candidiasis versus chronic recurrent vulvovaginal candidiasis: distinct diseases, different populations.
Day T, Sobel JD
Clinical microbiology reviews 2025; (38(2)):e0002025 doi:10.1128/cmr.00020-25.
PMID: 40434101
16
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
Nyirjesy P, Brookhart C, Lazenby G, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022; (74(Suppl_2)):S162-S168 doi:10.1093/cid/ciab1057.
PMID: 35416967
17
Non-albicans Candida and rare yeasts in vulvovaginal candidiasis: pathogen attribution, antifungal resistance, persistence, and species-informed management.
Yan Z, Cui Y, Li Y, et al.
Frontiers in microbiology 2026; (17()):1944046 doi:10.3389/fmicb.2026.1944046.
PMID: 42780976
18
Chronic recurrent vulvovaginitis is not only due to Candida.
Arechavala A, Negroni R, Santiso G, et al.
Revista iberoamericana de micologia 2021; (38(3)):132-137 doi:10.1016/j.riam.2021.03.002.
PMID: 34092515

This page explains the biology and diagnosis of vulvovaginal candidiasis for informational purposes only and does not constitute medical advice. A clinician should confirm the cause of your symptoms and recommend treatment for your situation.